Traders should monitor for potential sharp downside on the negative AdCom signal; the August 22 PDUFA decision remains the key binary event, but the vote significantly reduces odds of straightforward approval. Consider short-term puts or avoid long exposure until FDA decision.
Price Chart
Executive Summary
The FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted 9-3 against evidence supporting Deramiocel's effectiveness for DMD cardiomyopathy, a significant negative signal ahead of the August 22 PDUFA date. Although the vote is non-binding and the committee was supportive on upper limb function, the FDA typically follows AdCom recommendations, raising substantial approval risk for Capricor's lead asset.
Key Facts
- AdCom voted 9-3 against effectiveness of Deramiocel for DMD cardiomyopathy
- Committee vote is non-binding; PDUFA target action date is August 22, 2026
- Committee feedback on upper limb function was directionally supportive
- Deramiocel has Orphan Drug, RMAT, and Rare Pediatric Disease designations
Financial Impact
Negative AdCom vote significantly increases risk of non-approval or CRL for Capricor's lead asset; potential for substantial stock price decline given ~$380M market cap and single-asset focus
Risk Factors
- FDA may issue a Complete Response Letter (CRL) based on the AdCom vote
- Further delays or additional trials required for approval
- Potential stock price decline of 20-50% if CRL issued
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3336165 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | SC 13G/A | $7.27 $6.13 | ▲ +15.68% | ▲ +14.67% | $5.74 (+21.05%) |
Aug 24, 2026 9w ago | 8-K | $6.80 $9.91 | ▼ −45.74% | ▼ −45.27% | $5.74 (+15.59%) |
Aug 21, 2026 9w ago | Institutional Cluster | $6.29 $9.59 | ▲ +52.46% | ▲ +51.99% | $5.74 (−8.74%) |
Jul 30, 2026 12w ago | Press Release | $4.19 $4.18 | ▲ +0.24% | ▲ +3.86% | $5.74 (−36.99%) |
Jul 14, 2026 14w ago | 8-K | $20.35 $18.91 | ▼ −7.08% | ▼ −6.10% | $5.74 (−71.79%) |
Jun 29, 2026 16w ago | Insider Cluster | $24.08 $22.43 | ▼ −6.85% | ▼ −7.46% | $5.74 (−76.16%) |
Jun 26, 2026 17w ago | 8-K | $23.80 $22.43 | ▼ −5.76% | ▼ −7.14% | $5.74 (−75.88%) |
Jun 24, 2026 17w ago | Insider Cluster | $30.40 $23.07 | ▼ −24.11% | ▼ −25.67% | $5.74 (−81.12%) |
Jun 1, 2026 21w ago | Court Ruling | $27.34 $26.01 | ▼ −4.86% | ▼ −1.90% | $5.74 (−79.01%) |
May 12, 2026 23w ago | Press Release | $30.33 $26.92 | ▼ −11.24% | ▼ −10.09% | $5.74 (−81.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers